Kymera Therapeutics (KYMR) Net Margin (2019 - 2025)
Historic Net Margin for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to 2973.05%.
- Kymera Therapeutics' Net Margin fell 13027200.0% to 2973.05% in Q3 2025 from the same period last year, while for Sep 2025 it was 124000.84%, marking a year-over-year increase of 1241921000.0%. This contributed to the annual value of 7221.23% for FY2024, which is 70342300.0% down from last year.
- Latest data reveals that Kymera Therapeutics reported Net Margin of 2973.05% as of Q3 2025, which was down 13027200.0% from 667.6% recorded in Q2 2025.
- In the past 5 years, Kymera Therapeutics' Net Margin ranged from a high of 193.43% in Q4 2024 and a low of 2973.05% during Q3 2025
- In the last 5 years, Kymera Therapeutics' Net Margin had a median value of 296.75% in 2025 and averaged 517.53%.
- In the last 5 years, Kymera Therapeutics' Net Margin soared by 5129900bps in 2021 and then plummeted by -13027200bps in 2025.
- Quarter analysis of 5 years shows Kymera Therapeutics' Net Margin stood at 222.88% in 2021, then rose by 3bps to 216.03% in 2022, then surged by 86bps to 30.01% in 2023, then soared by 745bps to 193.43% in 2024, then crashed by -1637bps to 2973.05% in 2025.
- Its Net Margin stands at 2973.05% for Q3 2025, versus 667.6% for Q2 2025 and 296.75% for Q1 2025.